EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)LeitlinieOpen Access

Agreement among high-sensitivity cardiac troponin assays and non-invasive testing, clinical outcomes, and quality-of-care outcomes based on the 2020 European Society of Cardiology Guidelines

Júlia Karády iD, Thomas Mayrhofer, James L Januzzi iD, James E Udelson, Jerome L Fleg, Bela Merkely, Michael T Lu, William F Peacock, John T Nagurney, Wolfgang Koenig iD, Maros Ferencik, Udo Hoffmann

European Heart Journal: Acute Cardiovascular Care · 2024

DOI: 10.1093/ehjacc/zuad146 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2024. Verfasst von Júlia Karády und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St Suite 400, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Troponin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Quality-of-care and safety of patients with suspected acute coronary syndrome (ACS) would benefit if management was independent of which high-sensitivity cardiac troponin (hs-cTn) assay was used for risk stratification. We aimed to determine the concordance of hs-cTn assays to risk-stratify patients with suspected ACS according to the European Society of Cardiology (ESC) 2020 Guidelines. Methods and results Blood samples were obtained at arrival and at 2 h from patients with suspected ACS using four hs-cTn assays. The patients were classified into rule-out/observe/rule-in strata based on the ESC 2020 Guidelines. Concordance was determined among the assays for rule-out/observe/rule-in strata. The prevalences of significant underlying disease (≥50% stenosis on coronary computed tomography or inducible myocardial ischaemia on stress testing) and adjudicated ACS, plus quality-of-care outcomes, were compared. Among 238 patients (52.7 ± 8.0 years; 40.3% female), the overall concordance across assays to classify patients into rule-out/observe/rule-in strata was 74.0% (176/238). Platforms significantly differed for rule-out (89.9 vs. 76.5 vs. 78.6 vs. 86.6%, P < 0.001) and observe strata (6.7 vs. 20.6 vs. 17.7 vs. 9.2%, P < 0.001), but not for rule-in strata (3.4 vs. 2.9 vs. 3.8 vs. 4.2%, P = 0.62). Among patients in ruled-out strata, 19.1–21.6% had significant underlying disease and 3.3–4.2% had ACS. The predicted disposition of patients and cost-of-care differed across the assays (all P < 0.001). When compared with observed strata, conventional troponin-based management and predicted quality-of-care outcomes significantly improved with hs-cTn-based strategies (direct discharge: 21.0 vs. 80.3–90.8%; cost-of-care: $3889 ± 4833 vs. $2578 ± 2896–2894 ± 4371, all P < 0.001).

Conclusion

Among individuals with suspected ACS, patient management may differ depending on which hs-cTn assay is utilized. More data are needed regarding the implications of inter-assay differences. Trail registration NCT01084239.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeTroponinFemaleHumansMaleMiddle AgedBiomarkersCardiology

Stichwörter der Autor:innen

0/2 h diagnostic algorithmAcute coronary syndromeHigh-sensitivity troponin assayNon-invasive diagnostic testingQuality-of-care outcomes

Substanzen

BiomarkersTroponin

Autor:innen und Institutionen

  • Cardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St Suite 400, Boston, MA 02114, USA.
  • Heart and Vascular Center, Semmelweis University, 9-11 Gaál József Street, Budapest 1122, Hungary.
  • School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany.
  • Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Medicine, Tufts Medical Center, Boston, MA, USA.
  • Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.

ORCID-Profile: Júlia Karády, James L Januzzi, Wolfgang Koenig

Förderung

  • NHLBI NIH HHS
  • NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health

Zitieren

APA

Karády, J., Mayrhofer, T., Januzzi, J. L., Udelson, J. E., Fleg, J. L., Merkely, B., Lu, M. T., Peacock, W. F., Nagurney, J. T., Koenig, W., Ferencik, M., & Hoffmann, U. (2024). Agreement among high-sensitivity cardiac troponin assays and non-invasive testing, clinical outcomes, and quality-of-care outcomes based on the 2020 European Society of Cardiology Guidelines. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuad146

Vancouver

Karády J, Mayrhofer T, Januzzi JL, Udelson JE, Fleg JL, Merkely B, et al. Agreement among high-sensitivity cardiac troponin assays and non-invasive testing, clinical outcomes, and quality-of-care outcomes based on the 2020 European Society of Cardiology Guidelines. European Heart Journal: Acute Cardiovascular Care. 2024. doi:10.1093/ehjacc/zuad146

BibTeX
@article{Kardy2024,
  author = {Karády, Júlia and Mayrhofer, Thomas and Januzzi, James L and Udelson, James E and Fleg, Jerome L and Merkely, Bela and Lu, Michael T and Peacock, William F and Nagurney, John T and Koenig, Wolfgang and Ferencik, Maros and Hoffmann, Udo},
  title = {Agreement among high-sensitivity cardiac troponin assays and non-invasive testing, clinical outcomes, and quality-of-care outcomes based on the 2020 European Society of Cardiology Guidelines},
  journal = {European Heart Journal: Acute Cardiovascular Care},
  year = {2024},
  doi = {10.1093/ehjacc/zuad146}
}
Kostenlos starten →